Protecting blood stem cells from DNA damage
Official title: Protection of hematopoietic stem progenitor cells from endogenous DNA damage
Funded at Johns Hopkins University · NIH-11062869 · Data updated 2026-11-12
This study is looking for ways to protect important blood-making cells from damage caused by harmful substances, specifically for people with Fanconi anemia, to help prevent serious issues like bone marrow failure and cancer.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project start | April 21, 2025 |
| Project end | March 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $380,383 |
| NIH project number | 1R00HL177829-01 |
| Project ID | NIH-11062869 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with Fanconi anemia or those at risk of bone marrow failure due to DNA damage.
✕Less likely to help
Patients without any genetic predisposition to bone marrow failure or those not affected by DNA damage-related conditions may not benefit from this research.
What this research studies
This research investigates how to protect hematopoietic stem cells (HSCs), which are crucial for producing blood cells, from DNA damage caused by reactive aldehydes. The study will utilize advanced techniques like CRISPR technology to identify and enhance the enzymes that detoxify these harmful substances. By using a model that mimics human conditions, the researchers aim to discover new ways to prevent DNA damage in patients with Fanconi anemia, a condition that makes them particularly vulnerable. The ultimate goal is to develop therapies that can prevent bone marrow failure and related cancers.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that protect patients with Fanconi anemia from severe blood-related complications.
How similar studies have gone: Previous research has shown promise in using CRISPR technology for gene editing and enhancing cellular functions, indicating potential success for this novel approach.
Where this research is happening
-
Johns Hopkins University
Baltimore, United States Active
Researchers
- Principal investigator: Jung, Moonjung — Johns Hopkins University
- Study coordinator: Jung, Moonjung
Related research
Other NIH-funded projects on the same topics.
-
Targeting hidden brain injuries in iTTP to improve long-term brain health
A researcher aims to find out how silent brain injuries in people with immune thrombotic thrombocytopenic purpura (iTTP) happen, how they affect thinking and stroke risk, and how to prevent them.
-
Accelerated flap coverage for severe leg injuries: earlier reconstruction vs standard timing
This study tests whether doing early flap coverage after a severe leg injury lowers infection risk and improves healing for patients with open wounds and bone injury.
-
Placebo-controlled shunting for iNPH: does the surgery help with walking and balance?
A doctor-led trial at Johns Hopkins will test whether a shunt surgery improves walking and balance in older adults with idiopathic normal pressure hydrocephalus.
-
Omalizumab for COPD patients with allergen sensitization and exposure
A multicenter trial will test whether adding omalizumab helps people with COPD who are allergic to common indoor allergens and are exposed to them.
-
Johns Hopkins Total Worker Health Center focusing on mental health
A nationwide center at Johns Hopkins is working to improve mental health and well-being among workers by studying workplace health strategies and translating findings into practical tools.
-
Role of fat droplets in liver fat and inflammatory signals in NAFLD
A study at Johns Hopkins will explore how fat droplets in the liver influence molecules that drive inflammation and progression of non-alcoholic fatty liver disease (NAFLD) in adults.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.